All neutropenia articles
-
NewsStudy identifies serious infection risks linked to targeted cancer therapies
A major real-world study has found serious blood-related side effects associated with antibody-drug conjugates, an increasingly important class of targeted cancer therapies. Some ADCs were associated with substantial rates of severe neutropenia – dangerously low levels of infection-fighting white blood cells – and related complications.